TABLE 3.
Univariable analysis of factors associated with suboptimal timeliness of care in reference to those with optimal timeliness of care
| Univariable OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|
| Overall Lung and Oesophagogastric cancer | Referral Receipt to First Specialist Appointment | Referral to Diagnosis | Referral to Treatment | Diagnosis to MDM | MDM to Treatment | Diagnosis to Treatment | |
| Age at diagnosis (years) | 0.99 (0.96 to 1.04) | 1.03 (0.99 to 1.07) | 0.98 (0.94 to 1.02) | 1.02 (0.98 to 1.06) | 1.01 (0.97 to 1.06) | 0.99 (0.95 to 1.03) | |
| Residence in Greater City of Bendigo | 0.59 (0.24 to 1.44) | 0.93 (0.40 to 2.19) | 1.86 (0.77 to 4.45) | 1.05 (0.41 to 2.68) | 1.25 (0.44 to 3.54) | 1.96 (0.81 to 4.73) | |
| Male Gender | 0.75 (0.31 to 1.79) | 1.38 (0.56 to 3.37) | 1.17 (0.48 to 2.86) | 1.53 (0.59 to 4.05) | 1.68 (0.59 to 4.82) | 0.67 (0.27 to 1.69) | |
| Lung cancer a | 0.59 (0.25 to 1.40) | 0.34 (0.14 to 0.83)* | 0.73 (0.31 to 1.72) | 1.87 (0.73 to 7.79) | 0.79 (0.28 to 2.18) | 2.48 (1.01 to 6.09)* | |
| MDM | 2.06 (0.62 to 6.88) | 1.50 (0.54 to 4.17) | 2.92 (0.89 to 9.56) | n/a | n/a | 2.86 (0.88 to 9.27) | |
| Comorbidity | Respiratory | 2.40 (1.02 to 5.63)* | 1.18 (0.50 to 2.81) | 1.86 (0.77 to 4.45) | 2.53 (0.92 to 6.91) | 1.97 (0.68 to 5.70) | 2.15 (0.86 to 5.35) |
| Cardiovascular | 1.17 (0.51 to 2.70) | 1.50 (0.64 to 3.50) | 3.16 (1.32 to 7.54)* | 1.18 (0.46 to 3.00) | 1.18 (0.43 to 3.25) | 0.61 (0.25 to 1.47) | |
| Gastrointestinal | 1.73 (0.68 to 4.42) | 1.42 (0.51 to 3.94) | 3.21 (1.06 to 9.68)* | 0.75 (0.25 to 2.30) | 0.52 (0.17 to 1.56) | 2.17 (0.73 to 6.41) | |
| Metabolic | 0.56 (0.24 to 1.31) | 1.89 (0.78 to 4.59) | 2.46 (1.01 to 5.96)* | 0.82 (0.31 to 2.16) | 1.40 (0.48 to 4.08) | 1.04 (0.43 to 2.54) | |
| Cancer | 1.02 (0.38 to 2.73) | 3.89 (1.18 to 12.69)* | 2.15 (0.79 to 5.87) | 0.65 (0.17 to 2.52) | 2.35 (0.60 to 9.30) | 0.69 (0.23 to 2.12) | |
| Bone & Joint | 0.78 (0.27 to 2.28) | 0.85 (0.27 to 2.70) | 1.43 (0.48 to 4.29) | 0.62 (0.20 to 1.98) | 1.34 (0.37 to 4.79) | 2.40 (0.76 to 7.58) | |
| Any comorbidity | 1.06 (0.42 to 2.66) | 0.49 (0.19 to 1.26) | 0.41 (0.16 to 1.06) | 0.73 (0.28 to 1.91) | 0.48 (0.17 to 1.41) | 0.87 (0.35 to 2.18) | |
| Number of Comorbidities | 0.99 (0.88 to 1.12) | 0.90 (0.79 to 1.03) | 0.90 (0.79 to 1.02) | 0.95 (0.83 to 1.08) | 0.92 (0.79 to 1.06) | 0.92 (0.81 to 1.05) | |
| ECOG ≤ 2 b | 0.19 (0.03 to 1.25) | 5.00 (0.76 to 32.93) | 0.79 (0.13 to 5.01) | 0.95 (0.13 to 7.28) | 9.50 (0.83 to 109.24) | 0.63 (0.09 to 4.01) | |
| Metastatic disease c | 1.82 (0.65 to 5.08) | 3.81 (1.19 to 12.16)* | 2.32 (0.76 to 7.08) | 2.50 (0.74 to 8.45) | 2.93 (0.78 to 10.98) | 1.98 (0.66 to 5.94) | |
| Unknown stage d | 0.45 (0.18 to 1.11) | 0.97 (0.41 to 2.30) | 0.65 (0.28 to 1.54) | 1.33 (0.64 to 2.76) | 0.60 (0.21 to 1.71) | 0.95 (0.39 to 2.32) | |
| Oesophagogastric cancer—Univariable | |||||||
| Age at Diagnosis (years) | 1.02 (0.96 to 1.07) | 1.06 (<1.00 to 1.135) | 1.03 (0.97 to 1.09) | 1.06 (0.99 to 1.13) | 1.02 (0.96 to 1.09) | 0.98 (0.92 to 1.04) | |
| Residence in Greater City of Bendigo | 2.29 (0.58 to 9.03) | 2.50 (0.57 to 11.01) | 2.02 (0.51 to 7.94) | 1.50 (0.39 to 5.81) | 1.35 (0.29 to 6.38) | 0.28 (0.06 to 1.31) | |
| Male Gender | 0.78 (0.16 to 3.82) | 2.31 (0.38 to 14.21) | 1.67 (0.31 to 8.93) | 0.46 (0.08 to 2.79) | 3.64 (0.50 to 26.76) | 0.76 (0.12 to 4.64) | |
| MDM | 4.19 (0.46 to 37.94) | 8.27 (0.88 to 78.01) | 3.92 (0.37 to 42.20) | n/a | n/a | 1.40 (0.20 to 9.75) | |
| Comorbidity | Respiratory | 1.92 (0.43 to 8.58) | 2.00 (0.37 to 10.92) | 1.50 (0.34 to 6.70) | 1.71 (0.35 to 8.37) | 5.25 (0.54 to 50.64) | 6.60 (0.73 to 60.02) |
| Cardiovascular | 0.63 (0.14 to 2.88) | 1.04 (0.22 to 4.91) | 2.76 (0.57 to 13.29) | 3.50 (0.61 to 20.13) | n/a | 2.50 (0.44 to 14.23) | |
| Gastrointestinal | 2.08 (0.38 to 11.18) | 2.18 (0.31 to 15.29) | 7.50 (0.79 to 71.09) | 1.63 (0.26 to 10.32) | 3.21 (0.32 to 32.21) | n/a | |
| Metabolic | n/a | 0.62 (0.05 to 7.57) | 1.40 (0.20 to 9.66) | 1.63 (0.26 to 10.32) | n/a | 2.20 (0.22 to 22.20) | |
| Cancer | n/a | n/a | 0.88 (0.05 to 15.37) | n/a | n/a | n/a | |
| Bone & Joint | n/a | n/a | 0.88 (0.11 to 7.05) | 0.76 (0.09 to 5.81) | n/a | n/a | |
| Any comorbidity | 1.31 (0.34 to 5.09) | 0.67 (0.16 to 2.82) | 0.46 (0.11 to 1.85) | 0.49 (0.61 to 2.45) | 0.10 (0.01 to 0.95) | 0.20 (0.04 to 1.11) | |
| Number of comorbidities | 1.18 (0.89 to 1.57) | 0.98 (0.72 to 1.33) | 0.96 (0.76 to 1.20) | 0.93 (0.72 to 1.18) | 0.71 (0.46 to 1.08) | 0.78 (0.57 to 1.07) | |
| ECOG ≤ 2 b | n/a | n/a | n/a | n/a | n/a | n/a | |
| Metastatic disease c | 2.78 (0.48 to 16.03) | 1.67 (0.31 to 9.01) | 1.07 (0.19 to 5.91) | 0.28 (0.45 to 15.31) | 2.40 (0.29 to 19.78) | 3.43 (0.52 to 22.80) | |
| Unknown stage d | 0.62 (0.15 to 2.51) | 0.55 (0.11 to 2.73) | 0.50 (0.12 to 2.06) | 0.44 (0.11 to 1.85) | 0.46 (0.10 to 2.22) | 1.20 (0.28 to 5.15) | |
| Lung cancer‐Univariable | |||||||
| Age at Diagnosis | 0.99 (0.94 to 1.04) | 1.00 (0.95 to 1.06) | 0.94 (0.88 to 0.99)* | 0.96 (0.90 to 1.04) | 1.00 (0.94 to 1.07) | 0.99 (0.93 to 1.05) | |
| Residence in Greater City of Bendigo | 0.20 (0.05 to 0.82)* | 0.83 (0.25 to 2.72) | 2.11 (0.63 to 7.08) | 0.73 (0.19 to 2.81) | 1.22 (0.30 to 5.03) | 6.83 (1.83 to 25.40) | |
| Male Gender | 0.85 (0.29 to 2.49) | 1.54 (0.50 to 4.79) | 1.12 (0.37 to 3.35) | 2.29 (0.59 to 8.91) | 1.42 (0.37 to 5.47) | 0.40 (0.12 to 1.30) | |
| MDM | 1.19 (0.26 to 5.57) | 0.44 (0.09 to 2.30) | 2.81 (0.69 to 11.44) | n/a | n/a | 4.22 (0.79 to 22.62) | |
| Comorbidity | Respiratory | 2.39 (0.80 to 7.12) | 0.63 (0.21 to 1.91) | 1.97 (0.66 to 5.91) | 5.00 (1.20 to 20.92)* | 1.23 (0.32 to 4.74) | 2.13 (0.66 to 6.88) |
| Cardiovascular | 1.23 (0.38 to 4.05) | 0.93 (0.27 to 3.18) | 3.89 (1.15 to 13.14)* | 1.00 (0.25 to 4.08) | 0.17 (0.02 to 1.54) | 0.46 (0.11 to 1.89) | |
| Gastrointestinal | 1.42 (0.45 to 4.49) | 0.95 (0.94 to 3.30) | 2.15 (0.59 to 7.90) | 0.50 (0.11 to 2.37) | 0.19 (0.04 to 0.80)* | 1.33 (0.36 to 4.97) | |
| Metabolic | 0.55 (0.183 to 1.63) | 1.41 (0.46 to 4.30) | 3.02 (0.99 to 9.19) | 0.86 (0.23 to 3.25) | 0.77 (0.20 to 2.98) | 1.63 (0.51 to 5.23) | |
| Cancer | 0.93 (0.31 to 2.84) | 2.74 (0.77 to 9.76) | 2.37 (0.75 to 7.52) | 0.59 (0.32 to 7.50) | 1.83 (0.41 to 8.27) | 0.70 (0.19 to 2.59) | |
| Bone and joint | 1.10 (0.32 to 3.75) | 0.63 (0.17 to 2.29) | 1.62 (0.43 to 6.09) | 0.73 (0.17 to 3.13) | 0.64 (0.15 to 2.77) | 2.59 (0.70 to 9.62) | |
| Any comorbidity | 2.33 (0.35 to 15.17) | 1.84 (0.19 to 17.71) | 0.19 (0.02 to 1.98) | 0.23 (0.02 to 2.20) | n/a | 0.81 (0.12 to 5.34) | |
| Number of comorbidities | 0.99 (0.84 to 1.16) | 0.98 (0.81 to 1.18) | 0.86 (0.72 to 1.03) | 0.87 (0.69 to 1.06) | 1.00 (0.82 to 1.22) | 0.83 (0.68 to 1.02) | |
| ECOG ≤ 2 b | 0.23 (0.03 to 1.59) | 7.20 (1.01 to 51.39)* | 0.72 (0.11 to 4.82) | 0.83 (0.09 to 7.68) | 6.00 (0.51 to 70.67) | 0.30 (0.04 to 2.17) | |
| Metastatic disease c | 1.39 (0.38 to 5.07) | 7.50 (1.28 to 44.09) | 4.00 (0.89 to 18.01) | 2.40 (0.44 to 12.98) | 3.33 (0.61 to 18.15) | 1.80 (0.42 to 7.81) | |
| Unknown stage d | 0.38 (0.11 to 1.26) | 0.98 (0.32 to 2.99) | 0.74 (0.25 to 2.20) | 1.93 (0.55 to 6.73) | 0.76 (0.18 to 3.25) | 0.80 (0.24 to 2.66) | |
Note: NB, No significant results in the Multivariable analysis.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MDM, multidisciplinary team meeting; OR, odds ratio.
*
P < .05.
a
Reference to oesophagogastric cancer.
b
Reference to ECOG performance score of more than 2.
c
Reference to localised disease.
d
Reference to known stage.